Media release

DKSH Continues Strengthening its Healthcare Own Brands Business With the Acquisition of two Brands From Eisai

DKSH Continues Strengthening its Healthcare Own Brands Business With the Acquisition of two Brands From Eisai

DKSH has signed an agreement to acquire two pharma brands from Eisai for nine markets in Asia Pacific. The acquisition fits in DKSH's strategy to grow in higher value-added segments and services and solidifies DKSH Healthcare’s leading position in the region.

Zurich, Switzerland, November 7, 2022 – DKSH has signed an agreement to purchase two well-known pharma brands, Myonal and Merislon, from Eisai in Thailand, Indonesia, the Philippines (Myonal only), Malaysia, Singapore, Taiwan (Merislon only), Myanmar, Cambodia, and Laos. Myonal is a muscle-relaxant which is used to treat neck-shoulder-arm syndrome and Merislon is approved to treat vertigo and dizziness associated with inner-ear disorders. Both brands are recognized among medical professionals in Asia Pacific and have established safety profiles.

With the acquisition, DKSH continues its strategy to expand its Healthcare Own Brands portfolio and to grow in Asia Pacific. The acquired portfolio generates net sales of over CHF 15 million. DKSH already markets these products for Eisai in most of the nine Asian markets and with the acquisition now becomes full brand owner. DKSH will continue to outsource production to established manufacturers for this portfolio.

Bijay Singh, Head Business Unit Healthcare at DKSH, commented: “This acquisition is another indicator of our commitment to growing our Own Brands portfolio. We are excited about this development since it helps us solidifying our leading position in Asia Pacific.”